Moderna (0QF) Stock Price & Analysis
0QF Stock Chart & Stats
- Day’s Range
- CHF 201.45 - CHF 203.05
- 52-Week Range
- CHF 29.35 - CHF 203.05
- Previous Close
- CHF 189.82
- Volume
- N/A
- Average Volume (3M)
- 1
- Market Cap
- CHF 74.26B
- Enterprise Value
- CHF 24.02B
- Total Cash (Recent Filing)
- CHF 5.14B
- Total Debt (Recent Filing)
- CHF 1.29B
- Price to Earnings (P/E)
- ―
- Beta
- 0.59
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- -0.89
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength
Moderna retains substantial liquidity and manageable leverage, providing financial flexibility to fund research, launches, and commercial expansion. This cushion can support execution through ongoing losses, although continued cash use means the balance-sheet advantage depends on eventual operating improvement.
Respiratory Portfolio Expansion
Broader approvals and procurement access diversify Moderna beyond a single COVID product and create more opportunities to commercialize its respiratory platform. Expanded geographic reach can support recurring seasonal demand and strengthen the company’s position as its portfolio matures.
Cost Efficiency
Lower manufacturing, research, and selling costs indicate that Moderna is adapting its cost base to a post-pandemic revenue environment. Sustained efficiency gains could reduce cash burn and improve operating leverage as newer respiratory and pipeline products contribute more revenue.
Bears Say
Persistent Losses And Cash Burn
Ongoing operating losses and negative free cash flow mean Moderna is not currently self-funding its operations or pipeline. Continued cash consumption can reduce strategic flexibility over time, even with significant liquidity, unless revenue growth and margins recover materially.
COVID Revenue Exposure
Moderna remains exposed to weakening COVID vaccination demand while newer products are not yet assumed to contribute revenue in 2026. This creates a difficult transition from pandemic-era sales and increases the importance of successful respiratory launches and broader pipeline commercialization.
Norovirus Clinical Setback
The norovirus setback delays clarity on a potentially important pipeline program and extends the time and cost required to reach a definitive outcome. Additional enrollment and seasonal accrual also increase execution uncertainty while Moderna continues funding a broad development portfolio.
Moderna News
Moderna’s Next‑Gen Pediatric Covid Shot Enters Key Phase 2 Test: What Investors Should Watch
Moderna ($MRNA) announced an update on their ongoing clinical study. The study “A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in
Moderna’s Next Flu Move: New Pediatric mRNA-1010 Trial Targets Long-Term Vaccine Growth
Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new Phase 1 study titled “A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity,
0QF FAQ
What was Moderna’s price range in the past 12 months?
What is Moderna’s market cap?
When is Moderna’s upcoming earnings report date?
How were Moderna’s earnings last quarter?
Is Moderna overvalued?
Does Moderna pay dividends?
What is Moderna’s EPS estimate?
How many shares outstanding does Moderna have?
What happened to Moderna’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Moderna?
What is the TipRanks Smart Score and how is it calculated?
Moderna Stock Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Website
- www.modernatx.com
- Address
- 325 Binney Street, Cambridge, MA, 02142, US
Moderna (0QF) Earnings & Revenues
0QF Company Deck
0QF Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.
View all CH:0QF earnings summaries0QF Net sales Breakdown
- 61.68% U.S.
- 2.73% Europe
- 35.60% Rest of World
0QF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 6 | 0 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 12 | 0 | 0 |
